Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

NCT06354660 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the medication retatrutide compared to a placebo in adults with type 2 diabetes who do not have adequate blood sugar control through diet and exercise alone.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 537 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-04 · est. completion 2026-02

Where 48 sites · India, Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06354660 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC.
Placebo Drug

Administered SC.

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Type 2
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06354660 ↗